✦ LIBER ✦

A Risk-Benefit Assessment of Anti-Obesity Drugs

✍ Scribed by Professor Jaroslaw Kolanowski

Book ID: 119925063
Publisher: Springer International Publishing AG
Year: 1999
Tongue: English
Weight: 159 KB
Volume: 20
Category: Article
ISSN: 0114-5916
DOI: 10.2165/00002018-199920020-00003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term cost-benefit assessment of ant

Long-term cost-benefit assessment of anti-migraine drugs

✍ TJ Steiner 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB

Nonsteroidal Anti-Inflammatory Drugs, Ga

Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit-Risk

✍ Moore, Robert Andrew; Derry, Sheena; Simon, Lee S.; Emery, Paul 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB

A Benefit-Risk Assessment of Sibutramine

A Benefit-Risk Assessment of Sibutramine in the Management of Obesity

✍ Dr Enzo Nisoli, Michele O. Carruba 📂 Article 📅 2003 🏛 Springer International Publishing AG 🌐 English ⚖ 181 KB

FDA Approval of Obesity DrugsA Differenc

FDA Approval of Obesity DrugsA Difference in Risk-Benefit PerceptionsFDA Approval of Obesity Drugs

✍ Morrato, Elaine H. 📂 Article 📅 2012 🏛 American Medical Association 🌐 English ⚖ 53 KB

A Decision-Analysis Tool for Benefit-Ris

A Decision-Analysis Tool for Benefit-Risk Assessment of Nonprescription Drugs

✍ Brass, Eric P.; Lofstedt, Ragnar; Renn, Ortwin 📂 Article 📅 2013 🏛 Sage Publications 🌐 English ⚖ 163 KB

Safety Assessment of an Anti-Obesity Dru

Safety Assessment of an Anti-Obesity Drug (Sibutramine)

✍ Jerzy E. Tyczynski, Dr Denise M. Oleske, David Klingman, Cheryl P. Ferrufino, Wo 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 191 KB